{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:43:01Z","timestamp":1790678581080,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-2-1024"],"award-info":[{"award-number":["2024-2-1024"]}]},{"name":"Supported by Beijing Natural Science Foundation","award":["7232018"],"award-info":[{"award-number":["7232018"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Foundation of China","doi-asserted-by":"crossref","award":["92259302"],"award-info":[{"award-number":["92259302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00428-025-04332-x","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T22:25:54Z","timestamp":1764195954000},"page":"375-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases"],"prefix":"10.1007","volume":"489","author":[{"given":"Qingxia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinya","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-0331","authenticated-orcid":false,"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"3","key":"4332_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4332_CR2","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115\u2013132","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4332_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.5858\/arpa.2020-0047-RA","volume":"145","author":"RS Gonzalez","year":"2021","unstructured":"Gonzalez RS, Raza A, Propst R, Adeyi O, Bateman J, Sopha SC et al (2021) Recent advances in digestive tract tumors: updates from the 5th Edition of the World Health Organization \u201cBlue Book.\u201d Arch Pathol Lab Med 145(5):607\u2013626","journal-title":"Arch Pathol Lab Med"},{"key":"4332_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Lauren","year":"1965","unstructured":"Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31\u201349","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"1","key":"4332_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5230\/jgc.2024.24.e7","volume":"24","author":"J Shin","year":"2024","unstructured":"Shin J, Park YS (2024) Unusual or uncommon histology of gastric cancer. J Gastric Cancer 24(1):69\u201388","journal-title":"J Gastric Cancer"},{"key":"4332_CR6","doi-asserted-by":"crossref","unstructured":"Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","DOI":"10.6004\/jnccn.2022.0008"},{"issue":"5","key":"4332_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.annonc.2021.02.021","volume":"32","author":"A Athauda","year":"2021","unstructured":"Athauda A, Chau I (2021) Claudin 18.2-a FAST-moving target in gastric cancer? Ann Oncol 32(5):584\u2013586","journal-title":"Ann Oncol"},{"issue":"23","key":"4332_CR8","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14(23):7624\u20137634","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4332_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, Tureci O, Manikhas G, Lordick F, Rusyn A, Vynnychenko I et al (2021) FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32(5):609\u2013619","journal-title":"Ann Oncol"},{"issue":"10389","key":"4332_CR10","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401(10389):1655\u20131668","journal-title":"Lancet"},{"issue":"8","key":"4332_CR11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29(8):2133\u20132141","journal-title":"Nat Med"},{"issue":"3","key":"4332_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, Lotz G, Fanelli GN, Brignola S, Lanza C, Cappellesso R et al (2019) Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer 121(3):257\u2013263","journal-title":"Br J Cancer"},{"key":"4332_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae238","author":"Y Kwak","year":"2024","unstructured":"Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ et al (2024) Clinicopathologic and molecular characterization of stages II-IV gastric cancer with claudin 18.2 expression. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyae238","journal-title":"Oncologist"},{"issue":"5","key":"4332_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100712","volume":"38","author":"KE McHugh","year":"2025","unstructured":"McHugh KE, Pai RK, Grant RC, Gallinger S, Davison J, Ma C (2025) Claudin 18.2 expression in 1404 digestive tract adenocarcinomas including 1175 colorectal carcinomas: distinct colorectal carcinoma subtypes are claudin 18.2 positive. Mod Pathol 38(5):100712","journal-title":"Mod Pathol"},{"issue":"11","key":"4332_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100589","volume":"37","author":"M Fassan","year":"2024","unstructured":"Fassan M, Kuwata T, Matkowskyj KA, Rocken C, Ruschoff J (2024) Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach. Mod Pathol 37(11):100589","journal-title":"Mod Pathol"},{"issue":"7","key":"4332_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7):797\u2013805","journal-title":"Histopathology"},{"issue":"3","key":"4332_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4143\/crt.2019.718","volume":"52","author":"Y Park","year":"2020","unstructured":"Park Y, Koh J, Na HY, Kwak Y, Lee KW, Ahn SH et al (2020) PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Res Treat 52(3):661\u2013670","journal-title":"Cancer Res Treat"},{"issue":"1","key":"4332_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.gastro.2010.04.002","volume":"139","author":"HJ Song","year":"2010","unstructured":"Song HJ, Srivastava A, Lee J, Kim YS, Kim KM, Ki Kang W et al (2010) Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 139(1):84-92 e2","journal-title":"Gastroenterology"},{"issue":"3","key":"4332_CR19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21037\/jgo-22-462","volume":"13","author":"W Weng","year":"2022","unstructured":"Weng W, Zhang M, Ni S, Tan C, Xu M, Wang X et al (2022) Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer. J Gastrointest Oncol 13(3):1035\u20131045","journal-title":"J Gastrointest Oncol"},{"key":"4332_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae238","author":"Y Kwak","year":"2025","unstructured":"Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ et al (2025) Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyae238","journal-title":"Oncologist"},{"issue":"1","key":"4332_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-019-1594-8","volume":"17","author":"Y Yamagata","year":"2019","unstructured":"Yamagata Y, Saito K, Ban S, Fujii A, Oya M (2019) The origin of p40-negative and CDX2-positive primary squamous cell carcinoma of the stomach: case report. World J Surg Oncol 17(1):53","journal-title":"World J Surg Oncol"},{"key":"4332_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241255628","volume":"17","author":"A Petrillo","year":"2025","unstructured":"Petrillo A, Ottaviano M, Pompella L, Giunta EF, Pisapia P, Marte G et al (2025) Rare epithelial gastric cancers: a review of the current treatment knowledge. Ther Adv Med Oncol 17:17588359241255628","journal-title":"Ther Adv Med Oncol"},{"key":"4332_CR23","doi-asserted-by":"publisher","unstructured":"Gu Y, Liu Z, Sheng X, Dong L, Chen C, Xu H, et al. (2025) Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in gastric adenosquamous carcinoma. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-025-04044-2","DOI":"10.1007\/s00428-025-04044-2"},{"issue":"1","key":"4332_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/pin.12613","volume":"68","author":"A Shimizu","year":"2018","unstructured":"Shimizu A, Takahashi T, Kushima R, Sentani K, Yasui W, Matsuno Y (2018) An extremely rare case of Epstein-Barr virus-associated gastric carcinoma with differentiation to neuroendocrine carcinoma. Pathol Int 68(1):41\u201346","journal-title":"Pathol Int"},{"issue":"3","key":"4332_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/his.14230","volume":"78","author":"S Yamashita","year":"2021","unstructured":"Yamashita S, Abe H, Kunita A, Yamashita H, Seto Y, Ushiku T (2021) Programmed cell death protein 1\/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. Histopathology 78(3):381\u2013391","journal-title":"Histopathology"},{"issue":"6","key":"4332_CR26","doi-asserted-by":"publisher","first-page":"NP57","DOI":"10.1177\/0300891620952845","volume":"106","author":"B Ricco","year":"2020","unstructured":"Ricco B, Salati M, Reggiani Bonetti L, Dominici M, Luppi G (2020) PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease. Tumori 106(6):NP57\u2013NP62","journal-title":"Tumori"},{"issue":"1","key":"4332_CR27","first-page":"14","volume":"22","author":"S Ye","year":"2025","unstructured":"Ye S, Li J, Xu J (2025) Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects. Cancer Biol Med 22(1):14\u201320","journal-title":"Cancer Biol Med"},{"issue":"5","key":"4332_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","volume":"475","author":"M Dottermusch","year":"2019","unstructured":"Dottermusch M, Kruger S, Behrens HM, Halske C, Rocken C (2019) Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch 475(5):563\u2013571","journal-title":"Virchows Arch"},{"issue":"1","key":"4332_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47178-6","volume":"13","author":"HD Kim","year":"2023","unstructured":"Kim HD, Choi E, Shin J, Lee IS, Ko CS, Ryu MH et al (2023) Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci Rep 13(1):20047","journal-title":"Sci Rep"},{"issue":"8","key":"4332_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1369\/jhc.2009.953810","volume":"57","author":"A Shinozaki","year":"2009","unstructured":"Shinozaki A, Ushiku T, Morikawa T, Hino R, Sakatani T, Uozaki H et al (2009) Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling. J Histochem Cytochem 57(8):775\u2013785","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"4332_CR31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cncr.27724","volume":"119","author":"J Zhao","year":"2013","unstructured":"Zhao J, Liang Q, Cheung KF, Kang W, Lung RW, Tong JH et al (2013) Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer 119(2):304\u2013312","journal-title":"Cancer"},{"issue":"1","key":"4332_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y et al (2023) Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8(1):100762","journal-title":"ESMO Open"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04332-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04332-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04332-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:25:20Z","timestamp":1786785920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04332-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4332"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04332-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human tissue samples and clinical data were collected and used in accordance with the principles of the Declaration of Helsinki. The study was approved by the Ethics Committee of Peking University Cancer Hospital (approval no. 2024KT51).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}